American Society of Hematology

Schedule and Program for the ASH Meeting on Lymphoma Biology

The following programming corresponds to the 2018 ASH Meeting on Lymphoma Biology.

2:00 p.m. - 7:00 p.m.
Registration
5:20 p.m. – 6:05 p.m.
Opening Keynote Address

Michael Reth, PhD, University of Freiburg
B Cell Antigen Receptor Signaling of Normal and Transformed B Cells
6:05 p.m. – 8:00 p.m.
Welcome Reception and Exhibits
7:00 a.m. – 5:00 p.m.
Registration
7:00 a.m. – 8:00 a.m.
Breakfast and Exhibits
8:00 a.m. – 10:00 a.m.
The Germinal Center as the Target Site

Chair:
Riccardo Dalla-Favera, MD, Columbia University

Speakers:
Shane Crotty, PhD, La Jolla Institute for Allergy and Immunology
T Follicular Helper (Tfh) CD4 T cells, Germinal Centers, Immunodominance, and the Generation of Memory to Vaccines

David Dominguez-Sola, MD, PhD, Icahn School of Medicine at Mount Sinai
Germinal Center Dynamics in the Pathogenesis of B cell non-Hodgkin Lymphomas

Stefano Casola, MD, PhD, International Foundations of Medicine
Targeting BCR Function in Mature B-Cell Neoplasms: Opportunities, Challenges, and Warnings: Lessons From Mouse Models

Oral Abstract Presenters:
Katia Basso, PhD, Columbia University
MEF2B Instructs Germinal Center Development and Acts as an Oncogene in B Cell Lymphomagenesis

Vipul Shukla, PhD, La Jolla Institute for Allergy and Immunology
Tet Proteins Regulate Enhancer Function and Class Switch Recombination During B Cell Activation
10:00 a.m. – 10:15 a.m.
Networking Coffee Break
10:15 a.m. – 12:15 p.m.
Microenvironment Influences in Lymphoma

Chair:
Freda K. Stevenson, DPhil, University of Southampton Medical School

Speakers:
Hans-Guido Wendel, MD, Memorial Sloan Kettering Cancer Center
Immune Receptor Mutations in Lymphoma

Karin Tarte, PhD, INSERM U1236 & CHU Rennes
Follicular Lymphoma Cell Niche: Role and Heterogeneity of FL-CAF

Ron Levy, MD, Stanford School of Medicine
Combining Intratumoral Injections of Toll-Like Receptor Agonists With Checkpoint Antibodies

Oral Abstract Presenters:
Elena Viganò, PhD, BC Cancer Research Centre
Recurrent IL4R Somatic Mutations in Diffuse Large B-Cell lymphoma Lead to an Altered Gene Expression Profile and Changes in Tumor Microenvironment Composition

Olga Kutovaya, PhD, BC Cancer Research Centre
UBR5 Mutations in Mantle Cell Lymphoma Lead to Increased Proliferation Through a Cyclin D1-Dependent Mechanism
12:15 p.m. – 1:15 p.m.
Lunch and Exhibits
1:15 p.m. – 1:45 p.m.
Company Presentations (Cancelled) Free Time
1:45 p.m. – 4:00 p.m.
Continuing Conversations

Moderator:
Francesco Forconi, MD, PhD

Continuing Conversation on B-Cell Receptor-Associated Kinase Inhibition in Tumor and Normal B Cells in vivo and in vitro

Moderator:
Silvia Deaglio, MD, PhD

Continuing Conversation on Chronic Lymphocytic Leukemia Microenvironment and its Relevance for Tumor Progression

Moderators:
Laura Pasqualucci, MD and Ari Melnick, MD

Continuing Conversation on Epigenetic Mechanisms in Lymphoma – What are the Biggest Unanswered Questions?

Moderator:
David Dominguez-Sola, MD, PhD

Continuing Conversation on Germinal Center Biology, Dynamics and B cell Lymphomagenesis

Moderator:
Megan Lim, MD, PhD

Continuing Conversation on Mass Spectrometry-based Proteomics in the Identification of Novel Biologic Insights in T-cell Lymphomas

Moderator:
Andreas Strasser, MSc, PhD, FAA

Continuing Conversation on the Tumor Suppressor p53 – How Does it Prevent Cancer and How Can Mutant p53 be Targeted Therapeutically?
4:00 p.m. – 5:30 p.m.
Poster Presentations
5:30 p.m. – 7:00 p.m.
Dinner (provided)
7:00 p.m. – 9:00 p.m.
Discovery of Novel Pathogenic Mechanisms and Therapies in Lymphoma

Chair:
Ari Melnick, MD, Weill Cornell Medical College

Speakers:
Ari Melnick, MD, Weill Cornell Medical College
Harnessing the Epigenome for Immunotherapy of B-cell Lymphoma

Laura Pasqualucci, MD, Columbia University
Genetic Basis of Epigenetic Dysregulation in Germinal Center-Derived Lymphomas

Suzanne Cory, PhD, Walter and Eliza Hall Institute of Medical Research
From Translocation to Therapy: How Understanding the BCL-2 Cell Life/Death Switch Is Leading to More Effective Therapy

Oral Abstract Presenter:
Justin Taylor, MD, Memorial Sloan Kettering Cancer Center
Oncogenic Mutations in XPO1 Promote Lymphoid Transformation by Altering Nuclear-Cytoplasmic Localization of NFκB Signaling Intermediates

Ryan M. Young, PhD, National Cancer Institute, National Institutes of Health
Functional Proteogenomic Screens Reveal a Myd88-TLR9 B Cell Receptor Supercomplex in Diffuse Large B-Cell Lymphoma
7:00 a.m. – 5:00 p.m.
Registration
7:00 a.m. – 8:00 a.m.
Breakfast and Exhibits
8:00 a.m. – 9:45 a.m.
New Technologies and Diagnostics

Chair:
Ash A. Alizadeh, MD, PhD, Stanford University Medical Center

Speakers:
Michael Angelo, MD, PhD, Stanford University
Single Cell Analysis of Signaling

Ronald N. Germain, MD, PhD, National Institute of Allergy and Infectious Diseases, National Institutes of Health
Single Cell Imaging

Ash A. Alizadeh, MD, PhD, Stanford University Medical Center
Circulating Tumor DNA

Oral Abstract Presenter:
Daniel J. Hodson, MD, PhD, University of Cambridge
Engineering the Genetics Events of Lymphomagenesis in Normal Human B Cells for High-Throughput, Functional Prioritization of Lymphoma Driver Genes
9:45 a.m. – 10:00 a.m.
Networking Coffee Break
10:00 a.m. – 12:00 noon
Molecular Targeting

Chair:
Louis Staudt, MD, PhD, National Cancer Institute, National Institutes of Health

Speakers:
Anthony Letai, MD, PhD, Dana-Farber Cancer Institute
Mitochondria Tell You What You Need to Know to Treat Lymphoid Cancers

Andreas Strasser, MSc, PhD, FAA, Walter and Eliza Hall Institute of Medical Research
How Does the Tumor Suppressor p53 Protect Us From Developing Cancer?

Roberto Chiarle, MD, Boston Children's Hospital
Targeted Therapy and Resistance in Lymphoma

Oral Abstract Presenters:
Guangzhen Hu, PhD, Mayo Clinic
Targetability of Novel STAT3-JAK2 Fusions Identified in T-Cell Lymphoproliferative Disorder of the Gastrointestinal Tract

Daniel J. Landsburg, MD, Abramson Cancer Center
A Pooled Analysis of Relapsed/Refractory Diffuse Large B-Cell Lymphoma Patients Treated With the Dual PI3K and HDAC Inhibitor Fimepinostat (CUDC-907), Including Patients With MYC-Altered Disease
12:00 noon – 1:00 p.m.
Lunch and Exhibits
1:00 p.m. – 1:30 p.m.
Company Presentations (Cancelled) Free Time
1:30 p.m. – 3:15 p.m.
Molecular Targeting (continued)

Chair:
Margaret A. Shipp, MD, Dana-Farber Cancer Institute

Speakers:
Margaret A. Shipp, MD, Dana-Farber Cancer Institute
Targetable Genetic Signatures in Lymphoid Malignancies

Louis Staudt, MD, PhD, National Cancer Institute, National Institutes of Health
Precision Therapy of Lymphoma via Genomics

Renier J. Brentjens, MD, PhD, Memorial Sloan Kettering Cancer Center
CAR T cell Therapy: CARs and Armored CARs

Oral Abstract Presenter:
James A. Heward, PhD, Barts Cancer Institute, Queen Mary University of London
KDM5 Inhibition Is a Novel Therapeutic Strategy for the Treatment of KMT2D Mutant Lymphomas
3:15 p.m. – 3:45 p.m.
Networking Coffee Break
3:45 p.m. – 5:15 p.m.
Poster Presentations
5:15 p.m. – 6:45 p.m.
Dinner (provided)
6:45 p.m. - 8:45 p.m.
Molecular Pathogenesis of T-Cell Lymphoma

Chair:
Kojo S.J. Elenitoba-Johnson, MD, University of Pennsylvania

Speakers:
Laurence L. de Leval, MD, PhD, Lausanne University Hospital
Pathology and Genetic Lesions

Teresa Palomero, PhD, Columbia University
The Role of the RHOA G17V Mutation in the Pathogenesis of Angioimmunoblastic T-Cell Lymphoma (AITL)

Megan Lim, MD, PhD, University of Pennsylvania Perelman School of Medicine
Novel Insights Into Anaplastic Lymphoma Kinase-Mediated Pathogenetic Mechanisms in Anaplastic Large Cell Lymphoma

Oral Abstract Presenters:
Sayeef Mirza, MD, University of South Florida
Genomic Landscapes of Cutaneous T-Cell Lymphoma and Sezary Syndrome

Emmanuel Bachy, MD PhD, Lyon Sud Hospital
Whole-Genome Crispr/Cas9 Screens Uncover the C-Terminal Portion of the Long-Isoform of Cflip as Essential for Ptcl Survival
7:00 a.m. – 1:00 p.m.
Registration
7:00 a.m. – 8:00 a.m.
Breakfast and Exhibits
8:00 a.m. – 10:00 a.m.
B-Cell Malignancies

Chair:
Laura Pasqualucci, MD, Columbia University

Speakers:
Bertrand Nadel, PhD, Centre D'Immunologie De Marseille-Luminy
Integrative Single-Cell Analysis: A New Prism to Decipher Follicular Lymphoma Heterogeneity

Ralf Kuppers, PhD, University of Duisburg - Essen
Hodgkin Lymphoma

Elias Campo, MD, PhD, University of Barcelona
Molecular Heterogeneity in Mantle Cell Lymphoma

Oral Abstract Presenters:
Elena Battistello, Swiss Federal Institute of Technology in Lausanne
Multimodal Inhibition of B Cell Receptor Signaling in Diffuse Large B-Cell Lymphoma (DLBCL) Impacts DLBCL Evolution

Fen Zhu, University of Wisconsin School of Medicine and Public Health
Protein Arginine Methyltransferase 5 Is Upregulated by B Cell Antigen Receptor Signaling and Promotes the Survival of Diffuse Large B-Cell Lymphoma Cells
10:00 a.m. – 10:20 a.m.
Networking Coffee Break
10:20 a.m. – 12:20 p.m.
Chronic Lymphocytic Leukemia

Chair:
Elias Campo, MD, PhD, University of Barcelona

Speakers:
Silvia Deaglio, MD, PhD, University of Turin
Microenvironmental Interactions in Chronic Lymphocytic Leukemia

Davide Rossi, MD, PhD, Oncology Institute of Southern Switzerland
Clinical Implications of Gene Mutations in Chronic Lymphocytic Leukemia

Francesco Forconi, MD, PhD, University of Southampton
B-Cell Receptor-Associated Kinase Inhibitors in Chronic Lymphocytic Leukemia

Oral Abstract Presenters:
Yong Li, PhD, Cleveland Clinic
Non-Proteolytic Polyubiquitination of Myd88 L265p in Class Switching Recombination and B-Cell Oncogenesis

Robert N. Booher, PhD, Curis, Inc.
Preclinical Activity of IRAK4 Kinase Inhibitor CA-4948 Alone or in Combination With Targeted Therapies in Diffuse Large B-Cell and Mantle Cell Lymphoma
12:20 p.m. – 12:40 p.m.
Closing Remarks From Program Co-Chairs
back to top